Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 7/20 | 0.44 |
| ▸ | NMT2 | O60551 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 5/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4757632 | 0.87 | NMT1 (0.39) | NMT1NMT2MEN1HSP90AA1KMT2A | |
| SCHEMBL4757634 | 0.87 | CYP3A4 (0.38) | NMT1NMT2MEN1HSP90AA1KMT2A | |
| SCHEMBL4754553 | 0.85 | HSD17B10 (0.47) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1486736 | 0.83 | BRD4 (0.40) | NMT1NMT2MEN1HSP90AA1KMT2A | |
| SCHEMBL3871436 | 0.83 | TLR7 (0.41) | NMT1NMT2MEN1HSP90AA1KMT2A | |
| SCHEMBL4753495 | 0.83 | SMN1; SMN2 (0.43) | NMT1NMT2MEN1HSP90AA1KMT2A | |
| SCHEMBL4757146 | 0.82 | EGLN2 (0.39) | NMT1NMT2MEN1HSP90AA1KMT2A | |
| SCHEMBL4757662 | 0.81 | ACSS2 (0.38) | NMT1NMT2MEN1HSP90AA1KMT2A | |
| SCHEMBL1486682 | 0.81 | TLR7 (0.43) | NMT1NMT2MEN1HSP90AA1KMT2A | |
| SCHEMBL1486772 | 0.80 | TLR7 (0.54) | NMT1NMT2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163947-B2 | 1-Amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| WO-2006028451-A1 | 1-AMINO 1-H-IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20050054640-A1 | 1-Amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054640-A1 | 1-Amino 1H-imidazoquinolines | IL2, IFNG, IL4I1 | NMT1 2529/4885NMT2 2810/4885MEN1 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.